Title: Comparative Analysis of Epidemiological Research Output of Metabolic Dysfunction-Associated Steatotic Liver Disease and Alcohol-Associated Liver Disease: A Global Bibliometric Analysis, 2000–2025

The liver is the body's tireless chemical plant, filtering toxins, storing energy, and managing the flow of nutrients. For decades, doctors have known that this vital organ can be damaged in two primary ways: by the accumulation of fat driven by modern metabolic problems like obesity and diabetes, or by the direct toxicity of excessive alcohol consumption. Until recently, the fat-related condition was often called non-alcoholic fatty liver disease, a name that defined it by what it was not. In 2023, the medical community updated this term to metabolic dysfunction-associated steatotic liver disease, or MASLD, to better reflect the complex metabolic drivers behind the illness and to reduce the stigma that often surrounds it. The alcohol-related condition, known as alcohol-associated liver disease, or ALD, remains a stubborn and deadly cause of liver failure worldwide. Both conditions are now the leading causes of long-term liver illness, driving a global rise in cirrhosis and liver cancer. Yet, despite their shared burden on human health, the scientific community has never clearly mapped how much attention researchers give to each problem, or where that attention is coming from.

A team of researchers from Sri Lanka set out to fill this gap by conducting a global inventory of scientific papers published between the years 2000 and 2025. They did not perform new experiments on patients or analyze blood samples; instead, they performed a bibliometric analysis, a method that treats scientific literature itself as data. By searching through millions of records in major medical databases, they identified and categorized every epidemiological study—research that looks at how diseases spread and affect populations—that focused on either MASLD or ALD. Their goal was to count the papers, trace their origins, and see if the volume of research matched the severity of the diseases. They were looking for patterns in who is studying these conditions, where the studies are taking place, and whether the scientific world is paying equal attention to both threats.

The results revealed a stark imbalance. The researchers found 315 unique studies that met their criteria, but these were not evenly split. The vast majority, 292 papers, focused on MASLD, while only 32 papers addressed ALD. This disparity was consistent over time; on average, researchers published nearly fourteen papers a year on the metabolic condition, compared to just one and a half papers a year on the alcohol-related condition. The gap was so wide that for many years, there were no eligible studies on alcohol-related liver disease at all. When the researchers looked at the growth of these fields, they saw that interest in MASLD has been climbing steadily for two decades, whereas research on ALD has been sporadic, appearing in only five of the twenty-one years studied, with a sudden surge of activity in the final two years.

Where this research comes from tells an even more troubling story about global inequality. The scientists found that the wealth of the country where a study is conducted dictates whether the research happens at all. For both diseases, the majority of studies came from high-income nations. However, the divide was absolute for the alcohol-related condition: not a single study on ALD originated from a low-income country. Even in the broader category of metabolic liver disease, low-income nations contributed almost nothing, accounting for only one percent of the papers. The African region and the Eastern Mediterranean, areas projected to face the sharpest increases in liver disease in the coming decades, were virtually invisible in the scientific record. For MASLD, the Western Pacific region, driven largely by China and South Korea, was the most active, followed closely by Europe and the Americas. For ALD, the Americas led the way, heavily influenced by research from the United States.

The way researchers gathered their information also differed significantly between the two fields. Studies on the metabolic condition relied heavily on primary data, meaning scientists went out and collected new information directly from patients or communities, often to build detailed clinical profiles. In contrast, the few studies on alcohol-related liver disease leaned more on secondary data, such as existing national health surveys, insurance records, or global burden estimates. This suggests that studying the metabolic condition is often a matter of targeted, on-the-ground investigation, while research into alcohol-related damage frequently depends on piecing together large-scale, pre-existing datasets. This difference may reflect the difficulty of collecting fresh data on alcohol use, where stigma and under-reporting can make direct questioning unreliable.

Despite the massive difference in the number of papers, the impact of the research, once adjusted for how long the papers have been available to be read, was surprisingly similar. When the researchers looked at how often the papers were cited by other scientists, the average rate of citation per year was nearly identical for both fields. This indicates that the few papers published on alcohol-related liver disease are just as influential and important as the many papers on the metabolic condition. Furthermore, a slightly higher proportion of the alcohol-related studies appeared in the most prestigious, top-tier medical journals, though the researchers noted this trend did not reach a level of statistical certainty.

The study also highlighted a blind spot in the current understanding of liver disease: the interaction between the two conditions. A growing number of people suffer from both metabolic dysfunction and significant alcohol consumption, a complex overlap that researchers call MetALD. Yet, the literature is almost entirely silent on this combined threat. The researchers found that the scientific community has largely treated these two causes of liver damage as separate silos, failing to investigate how they might worsen each other.

The authors of the study conclude that the current landscape of liver research is misaligned with the actual burden of disease. While the metabolic condition has attracted a flood of attention, the alcohol-related condition has been neglected, and both have been studied almost exclusively by wealthy nations, leaving the populations most at risk in low-income regions without a voice in the scientific conversation. The researchers argue that this gap is not just a matter of numbers, but of justice and effectiveness. Without data from the regions where liver disease is rising fastest, the global medical community cannot develop treatments or prevention strategies that work for everyone. The path forward requires a deliberate shift in funding and priorities to ensure that the science of liver disease reflects the reality of the people it is meant to serve.